

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 12, 2026 (the “**Prospectus**”) issued by HJ Science Co., Ltd. (華健未來(成都)科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.

In connection with the Global Offering, CLSA Limited, as stabilizing manager (the “**Stabilizing Manager**”), or any person acting for it, on behalf of the Underwriter, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting for it) to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager (or any person acting for it) and may be discontinued at any time. Any such stabilizing action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors of the Offer Shares should note that the Sole Overall Coordinator (acting in such capacity and as the Hong Kong Underwriter) shall be entitled to terminate its obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, June 23, 2026).



HJ Science Co., Ltd.

華健未來(成都)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

| | |
|---|--|
| Number of Offer Shares under the Global Offering | : 13,600,000 H Shares (subject to the Over-allotment Option) |
| Number of Hong Kong Offer Shares | : 1,360,000 H Shares |
| Number of International Offer Shares | : 12,240,000 H Shares (subject to the Over-allotment Option) |
| Offer Price | : HK\$81.80 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565%, and AFRC transaction levy of 0.00015% |
| Nominal Value | : RMB1.00 per Share |
| Stock Code | : 6132 |

Sole Sponsor, Sponsor-Overall Coordinator, Sole Overall Coordinator, Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager



CITIC SECURITIES

HJ SCIENCE CO., LTD. / 華健未來（成都）科技股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus issued by the Company.

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

| Company information | |
|----------------------------|----------------|
| Stock code | 6132 |
| Stock short name | HJ SCIENCE-B |
| Dealings commencement date | June 23, 2026* |

**see note at the end of the announcement*

| Price Information | |
|-------------------|-----------|
| Offer Price | HK\$81.80 |

| Offer Shares and Share Capital | |
|---|---------------------|
| Number of Offer Shares (before exercise of Over-allotment Option) | 13,600,000 H Shares |
| Final Number of Offer Shares in Hong Kong Public Offering | 1,360,000 H Shares |
| Final Number of Offer Shares in International Offering (before exercise of Over-allotment Option) | 12,240,000 H Shares |
| Number of issued shares upon Listing (before exercise of Over-allotment Option) | 73,599,605 Shares |

| Over-allocation | |
|---------------------------------------|--------------------|
| Number of Offer Shares over-allocated | 2,040,000 H Shares |

Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.

| Proceeds | |
|---|---------------------|
| Gross proceeds (Note) | HK\$1,112.5 million |
| Less: Estimated listing expenses payable based on Offer Price | HK\$93.7 million |
| Net proceeds | HK\$1,018.7 million |

Note: Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" of the Prospectus. Any discrepancies in the table between the aggregate amount and the sums of individual amounts listed therein are due to rounding.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

| | |
|--|----------------|
| | |
| No. of valid applications | 173,284 |
| No. of successful applications | 13,418 |
| Subscription level | 2,007.60 times |
| Reallocation | N/A |
| No. of Offer Shares initially available under the Hong Kong Public Offering | 1,360,000 |
| No. of Offer Shares reallocated from the International Offering | N/A |
| Final no. of Offer Shares under the Hong Kong Public Offering | 1,360,000 |
| % of Offer Shares under the Hong Kong Public Offering to the Global Offering (before exercise of Over-allotment Option) | 10.00% |

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

| | |
|---|------------|
| | |
| No. of placees | 91 |
| Subscription Level | 7.00 times |
| No. of Offer Shares initially available under the International Offering | 12,240,000 |
| Final no. of Offer Shares under the International Offering (before exercise of Over-allotment Option) | 12,240,000 |
| % of Offer Shares under the International Offering to the Global Offering (before exercise of Over-allotment Option) | 90.00% |

The Directors confirm that, to the best of their knowledge, information and belief, save for consent under paragraph 1C(2) of Appendix F1 to the Listing Rules, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

| <i>Investor</i> ^{Note 1} | <i>No. of Offer Shares allocated</i> | <i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i> | <i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i> | <i>Existing shareholders or their close associates</i> |
|---|--------------------------------------|--|--|--|
| Foresight Global Superior Choice SPC — Global Superior Choice Fund 1 SP, Foresight Global Superior Choice SPC — Vision Fund 1 SP, Foresight Global Superior Choice SPC — Horizon Fund 1 SP, Foresight Global Superior Choice SPC — Horizon Next Fund SP and Foresight International Series — Foresight China Equity Fund (collectively, “ Foresight Funds ”) | 2,395,400 | 17.61% | 3.25% | No |
| Key Broad Future Limited (凱博未來有限公司) (“ Key Broad ”) | 2,395,400 | 17.61% | 3.25% | No |
| LBC HK Opportunity Fund Limited (“ LBC HK ”) | 479,000 | 3.52% | 0.65% | No |
| Sage Partners Master Fund (“ Sage Partners ”) | 383,200 | 2.82% | 0.52% | No |
| Panjing Harbourview Investment Fund (盤京港景投資基金) (“ Panjing Fund ”) | 287,400 | 2.11% | 0.39% | No |
| Taikang Life Insurance Co., Ltd. (泰康人壽保險有限責任公司) (“ Taikang Life ”) | 287,400 | 2.11% | 0.39% | No |
| Total | 6,227,800 | 45.79% | 8.46% | |
| <p><i>Notes:</i></p> <p>1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.</p> | | | | |

Allotees with Consents Obtained

| <i>Investor</i> | <i>No. of Offer Shares allocated</i> | <i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i> | <i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i> | <i>Relationship</i> |
|--|--------------------------------------|--|--|--|
| Allotees with consents under paragraph 1C(1) of Appendix F1 to the Listing Rules (the "Placing Guidelines") in relation to allocations to connected clients ^{Note 1} | | | | |
| CITIC Securities International Capital Management Limited ("CSI") | 213,000 | 1.57% | 0.29% | Connected client as a placee |
| Shanxi Securities International Asset Management Limited ("SSIAM") | 244,400 | 1.80% | 0.33% | Connected client as a placee |
| Allottee with consent under paragraph 1C(2) of the Placing Guidelines in relation to allocation to a close associate of existing Shareholders | | | | |
| Wealth Shine Asia Pacific Limited ("Wealth Shine") Note 2 | 96,800 | 0.71% | 0.13% | A close associate of existing Shareholders |
| <p><i>Notes:</i></p> <p>1. For details of the consents under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed "Others / Additional Information – Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines" in this announcement.</p> <p>2. Ruiji Phase III Venture Capital Partnership (Limited Partnership) (安義瑞吉三期創業投資合夥企業(有限合夥)) ("Ruiji Phase III") and Anyi Ruiji Phase X Venture Capital Partnership Enterprise (Limited Partnership) (安義瑞吉十期創業投資合夥企業 (有限合夥)) ("Ruiji Phase X") own approximately 1.72% and 1.11%, respectively, of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 2.44% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by Wealth Shine under the International Offering. For further details, please refer to the section headed "Others / Additional Information – Placing to a close associate of existing Shareholders as placee with a prior consent under paragraph 1C(2) of the Placing Guidelines" in this announcement.</p> | | | | |

LOCK-UP UNDERTAKINGS

Controlling Shareholders

| <i>Name</i> | <i>Number of Shares held in the Company subject to lock-up undertakings immediately upon Listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment</i> | <i>Last day subject to the lock-up undertakings</i> Note 2 |
|-------------|--|---|---|
|-------------|--|---|---|

| | | <i>Option is not exercised)</i> | |
|--|-------------------|---------------------------------|---------------|
| Dr. Ji Jianxin (姬建新) (“ Dr. Ji ”) Note 1 | 12,424,624 | 16.88% | June 22, 2027 |
| Chengdu Wenshao Enterprise Management Center (Limited Partnership) (成都聞韶企業管理中心(有限合夥)) (“ Chengdu Wenshao ”) Note 1 | 19,971,379 | 27.14% | June 22, 2027 |
| Suzhou Jishitang Enterprise Management Center (Limited Partnership) (蘇州積石堂企業管理中心(有限合夥)) (“ Suzhou Jishitang ”) Note 1 | 2,097,440 | 2.85% | June 22, 2027 |
| Total | 34,493,443 | 46.87% | |

Notes:

1. Dr. Ji, Chengdu Wenshao and Suzhou Jishitang will be regarded as a group of Controlling Shareholders upon Listing. For further details, please refer to “Relationship with our Controlling Shareholders” in the Prospectus.
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing Shareholders ends on June 22, 2027, being 12 months following the Listing Date.

Cornerstone Investors

| <i>Name</i> | <i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings</i> ^{Note 2} |
|-----------------|--|--|---|
| Foresight Funds | 2,395,400 | 3.25% | December 22, 2026 |
| Key Broad | 2,395,400 | 3.25% | December 22, 2026 |
| LBC HK | 479,000 | 0.65% | December 22, 2026 |
| Sage Partners | 383,200 | 0.52% | December 22, 2026 |
| Panjing Fund | 287,400 | 0.39% | December 22, 2026 |
| Taikang Life | 287,400 | 0.39% | December 22, 2026 |
| Total | 6,227,800 | 8.46% | |

| <i>Name</i> | <i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings</i> ^{Note 2} |
|-------------|--|--|---|
|-------------|--|--|---|

Notes:

- In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December 22, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.*

Pre-IPO Investors (as defined in the "History, Development and Corporate Structure" section of the Prospectus)

| <i>Name</i> | <i>Number of shares held in the Company subject to lock-up undertakings upon listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings</i> ^{Note 1} |
|--|--|--|---|
| (SDIC) VC Fund (Shanghai) of Technology Transfer and Commercialization (Limited Partnership) (國投(上海)科技成果轉化創業投資基金企業(有限合夥)) | 5,520,100 | 7.50% | June 22, 2027 |
| Suzhou Junlian Xinkang Venture Capital Partnership (Limited Partnership) (蘇州君聯欣康創業投資合夥企業(有限合夥)) | 4,246,253 | 5.77% | June 22, 2027 |
| Chongqing Jiangjin District Private Equity Investment Fund Partnership (Limited Partnership) (重慶市江津區私募股權投資基金合夥企業(有限合夥)) | 2,222,218 | 3.02% | June 22, 2027 |
| Chongqing Chengyu Tuanjie Lake Strategic Emerging Industry Private Equity Investment Fund Partnership (Limited Partnership) (重慶市成渝團結湖戰略性新興產業私募 | 1,777,751 | 2.42% | June 22, 2027 |

| <i>Name</i> | <i>Number of shares held in the Company subject to lock-up undertakings upon listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings</i> ^{Note 1} |
|--|--|--|---|
| 股權投資基金合夥企業(有限合夥)) | | | |
| Ningbo Huaige Ruixin Venture Capital Partnership Enterprise (Limited Partnership) (寧波懷格銳信創業投資合夥企業(有限合夥)) | 1,617,322 | 2.20% | June 22, 2027 |
| Shanghai Junshi Biosciences Co., Ltd. (上海君實生物醫藥科技股份有限公司) | 1,261,749 | 1.71% | June 22, 2027 |
| Chengdu Peikun Jingrong Venture Capital Partnership (Limited Partnership) (成都沛坤菁蓉創業投資合夥企業(有限合夥)) | 1,204,357 | 1.64% | June 22, 2027 |
| Anyi Ruiji Phase III Venture Capital Partnership (Limited Partnership) (安義瑞吉三期創業投資合夥企業(有限合夥)) | 1,032,356 | 1.40% | June 22, 2027 |
| Sichuan Science and Technology Achievement Transformation Equity Investment Fund Partnership (Limited Partnership) (四川省科技成果轉化股權投資基金合夥企業(有限合夥)) | 946,326 | 1.29% | June 22, 2027 |
| Xiamen Jianfa Emerging Industries Equity Investment Partnership No. 2 (Limited Partnership) (廈門建發新興產業股權投資貳號合夥企業(有限合夥)) | 876,544 | 1.19% | June 22, 2027 |
| Zhang Naiye (張乃燁) | 876,544 | 1.19% | June 22, 2027 |
| Hefei Xingtai Huike Venture Capital Partnership (Limited Partnership) (合肥興泰慧科創業投資合夥企業(有限合夥)) | 666,671 | 0.91% | June 22, 2027 |

| <i>Name</i> | <i>Number of shares held in the Company subject to lock-up undertakings upon listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings</i> ^{Note 1} |
|--|--|--|---|
| Anyi Ruiji Phase X Venture Capital Partnership Enterprise (Limited Partnership) (安義瑞吉十期創業投資合夥企業(有限合夥)) | 666,662 | 0.91% | June 22, 2027 |
| Suzhou Yuanju Fanmao Investment Partnership Enterprise (Limited Partnership) (蘇州元聚帆茂投資合夥企業(有限合夥)) | 606,591 | 0.82% | June 22, 2027 |
| Chengdu Chunlei Xingming Technology Venture Capital Partnership Enterprise (Limited Partnership) (成都春壘星溟科技創業投資合夥企業(有限合夥)) | 499,997 | 0.68% | June 22, 2027 |
| Wuxi Runyuan Biopharmaceutical Venture Capital Partnership (Limited Partnership) (無錫潤元生物醫藥創業投資合夥企業(有限合夥)) | 444,467 | 0.60% | June 22, 2027 |
| Fuzhou Huace Xinming Pharmaceutical Investment Partnership Enterprise (Limited Partnership) (福州華策新明醫藥投資合夥企業(有限合夥)) | 444,442 | 0.60% | June 22, 2027 |
| Hefei Baohe District Linghang Venture Capital Fund Partnership Enterprise (Limited Partnership) (合肥市包河區領航創業投資基金合夥企業(有限合夥)) | 444,442 | 0.60% | June 22, 2027 |
| Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)) | 103,212 | 0.14% | June 22, 2027 |

| <i>Name</i> | <i>Number of shares held in the Company subject to lock-up undertakings upon listing</i> | <i>% of shareholding in the Company subject to lock-up undertakings upon listing (assuming the Over-allotment Option is not exercised)</i> | <i>Last day subject to the lock-up undertakings ^{Note 1}</i> |
|---|--|--|---|
| Chengdu Peikun Songfu Technology Partnership (Limited Partnership) (成都沛坤宋富科技合夥企業(有限合夥)) | 48,158 | 0.07% | June 22, 2027 |
| Total | 25,506,162 | 34.66% | |

Notes:

- 1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.*

PLACEE CONCENTRATION ANALYSIS

| Placees* | Number of H Shares allotted | Allotment as % of International Offering (assuming the Over-allotment Option is not exercised) | Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is not exercised) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued) | Number of Shares held upon Listing | % of total issued share capital upon Listing (assuming the Over-allotment Option is not exercised) | % of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued) |
|----------|-----------------------------|--|--|--|--|------------------------------------|--|--|
| Top 1 | 2,395,400 | 19.57% | 16.77% | 17.61% | 15.32% | 2,395,400 | 3.25% | 3.17% |
| Top 5 | 7,576,000 | 61.90% | 53.05% | 55.71% | 48.44% | 7,576,000 | 10.29% | 10.02% |
| Top 10 | 10,449,000 | 85.37% | 73.17% | 76.83% | 66.81% | 10,449,000 | 14.20% | 13.81% |
| Top 25 | 13,001,900 | 106.22% | 91.05% | 95.60% | 83.13% | 14,700,918 | 19.97% | 19.44% |

Note

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

| H Shareholders* | Number of H Shares allotted | Allotment as % of International Offering (assuming the Over-allotment Option is not exercised) | Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is not exercised) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued) | Number of H Shares held upon Listing | % of total issued H Share capital upon Listing (assuming the Over-allotment Option is not exercised) | % of total issued H share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued) | Number of Shares held upon Listing |
|-----------------|-----------------------------|--|--|--|--|--------------------------------------|--|--|------------------------------------|
| Top 1 | - | 0.00% | 0.00% | 0.00% | 0.00% | 34,493,443 | 46.87% | 45.60% | 34,493,443 |
| Top 5 | 2,395,400 | 19.57% | 16.77% | 17.61% | 15.32% | 50,655,165 | 68.83% | 66.97% | 50,655,165 |
| Top 10 | 4,887,600 | 39.93% | 34.23% | 35.94% | 31.25% | 59,525,648 | 80.88% | 78.70% | 59,525,648 |
| Top 25 | 10,545,800 | 86.16% | 73.85% | 77.54% | 67.43% | 70,100,963 | 95.25% | 92.68% | 70,100,963 |

Note

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

| Shareholders* | Number of H Shares allotted | Allotment as % of International Offering (assuming the Over-allotment Option is not exercised) | Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is not exercised) | Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued) | Number of H Shares held upon Listing | Number of Shares held upon Listing | % of total issued Share capital upon Listing (assuming the Over-allotment Option is not exercised) | % of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued) |
|---------------|--------------------------------|---|---|--|--|--|--|---|---|
| Top 1 | - | 0.00% | 0.00% | 0.00% | 0.00% | 34,493,443 | 34,493,443 | 46.87% | 45.60% |
| Top 5 | 2,395,400 | 19.57% | 16.77% | 17.61% | 15.32% | 50,655,165 | 50,655,165 | 68.83% | 66.97% |
| Top 10 | 4,887,600 | 39.93% | 34.23% | 35.94% | 31.25% | 59,525,648 | 59,525,648 | 80.88% | 78.70% |
| Top 25 | 10,545,800 | 86.16% | 73.85% | 77.54% | 67.43% | 70,100,963 | 70,100,963 | 95.25% | 92.68% |

Note

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

| NO. OF SHARES APPLIED FOR | NO. OF VALID APPLICATIONS | BASIS OF ALLOTMENT / BALLOT | APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR |
|--------------------------------------|--------------------------------------|---|---|
| POOL A | | | |
| 100 | 81,913 | 1,638 out of 81,913 to receive 100 Shares | 2.00% |
| 200 | 8,450 | 215 out of 8,450 to receive 100 Shares | 1.27% |
| 300 | 4,357 | 128 out of 4,357 to receive 100 Shares | 0.98% |
| 400 | 2,851 | 93 out of 2,851 to receive 100 Shares | 0.82% |
| 500 | 3,371 | 118 out of 3,371 to receive 100 Shares | 0.70% |
| 600 | 12,470 | 467 out of 12,470 to receive 100 Shares | 0.62% |
| 700 | 1,814 | 72 out of 1,814 to receive 100 Shares | 0.57% |
| 800 | 1,076 | 45 out of 1,076 to receive 100 Shares | 0.52% |
| 900 | 874 | 38 out of 874 to receive 100 Shares | 0.48% |
| 1,000 | 8,505 | 381 out of 8,505 to receive 100 Shares | 0.45% |
| 1,500 | 2,514 | 130 out of 2,514 to receive 100 Shares | 0.34% |
| 2,000 | 2,125 | 121 out of 2,125 to receive 100 Shares | 0.28% |
| 2,500 | 1,454 | 90 out of 1,454 to receive 100 Shares | 0.25% |
| 3,000 | 1,418 | 93 out of 1,418 to receive 100 Shares | 0.22% |
| 3,500 | 1,009 | 70 out of 1,009 to receive 100 Shares | 0.20% |
| 4,000 | 1,259 | 92 out of 1,259 to receive 100 Shares | 0.18% |
| 4,500 | 920 | 70 out of 920 to receive 100 Shares | 0.17% |
| 5,000 | 1,991 | 157 out of 1,991 to receive 100 Shares | 0.16% |
| 6,000 | 1,587 | 133 out of 1,587 to receive 100 Shares | 0.14% |
| 7,000 | 1,367 | 121 out of 1,367 to receive 100 Shares | 0.13% |
| 8,000 | 1,191 | 111 out of 1,191 to receive 100 Shares | 0.12% |
| 9,000 | 942 | 91 out of 942 to receive 100 Shares | 0.11% |
| 10,000 | 5,288 | 531 out of 5,288 to receive 100 Shares | 0.10% |

| | | | |
|--------|-------------|---|-------|
| 20,000 | 3,418 | 438 out of 3,418 to receive 100 Shares | 0.06% |
| 30,000 | 2,480 | 366 out of 2,480 to receive 100 Shares | 0.05% |
| 40,000 | 1,710 | 279 out of 1,710 to receive 100 Shares | 0.04% |
| 50,000 | 1,387 | 245 out of 1,387 to receive 100 Shares | 0.04% |
| 60,000 | 2,484 | 467 out of 2,484 to receive 100 Shares | 0.03% |
| | <hr/> | Total number of Pool A successful applicants: | |
| | 160,225 | 6,800 | |
| | <hr/> <hr/> | | |

POOL B

| | | | |
|---------|-------------|---|-------|
| 70,000 | 4,235 | 1,503 out of 4,235 to receive 100 Shares | 0.05% |
| 80,000 | 1,293 | 493 out of 1,293 to receive 100 Shares | 0.05% |
| 90,000 | 748 | 304 out of 748 to receive 100 Shares | 0.05% |
| 100,000 | 2,337 | 1,007 out of 2,337 to receive 100 Shares | 0.04% |
| 150,000 | 1,188 | 638 out of 1,188 to receive 100 Shares | 0.04% |
| 200,000 | 836 | 526 out of 836 to receive 100 Shares | 0.03% |
| 250,000 | 511 | 363 out of 511 to receive 100 Shares | 0.03% |
| 300,000 | 360 | 282 out of 360 to receive 100 Shares | 0.03% |
| 350,000 | 203 | 173 out of 203 to receive 100 Shares | 0.02% |
| 400,000 | 206 | 189 out of 206 to receive 100 Shares | 0.02% |
| 450,000 | 109 | 107 out of 109 to receive 100 Shares | 0.02% |
| 500,000 | 204 | 100 Shares plus 7 out of 204 to receive additional 100 Shares | 0.02% |
| 600,000 | 137 | 100 Shares plus 20 out of 137 to receive additional 100 Shares | 0.02% |
| 680,000 | 692 | 100 Shares plus 155 out of 692 to receive additional 100 Shares | 0.02% |
| | <hr/> | Total number of Pool B successful applicants: 6,618 | |
| | 13,059 | | |
| | <hr/> <hr/> | | |

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules in respect of which consents have been

obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS / ADDITIONAL INFORMATION

Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, consents under paragraph 1C(1) of the Placing Guidelines to permit certain Offer Shares to be placed to connected clients of connected distributors under the International Offering pursuant to the Placing Guidelines. Details of the placement to connected clients are set out below. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consents granted by the Stock Exchange. Please also refer to the section headed "Allotees with Consents Obtained" in this announcement for details.

Connected Clients holding the beneficial interest of the Offer Shares on behalf of independent third parties

| Connected Distributor | Connected Client | Relationship with the Connected Distributor | Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for independent third parties | Number of Offer Shares to be allocated to the connected client | Appropriate percentage of total number of Offer Shares (assuming the Over-allotment Option is not exercised) | Approximate percentage of total issued share capital in the Company upon Listing (assuming the Over-allotment Option is not exercised) |
|---|-------------------------|--|--|---|---|---|
| CLSA Limited ("CLSA") | CSI | CSI is a member of the same group of companies as CLSA | Non-discretionary basis | 213,000 | 1.57% | 0.29% |
| Shanxi Securities International Limited ("SSI") <small>Note 2</small> | SSIAM | Both SSI and SSIAM are ultimately controlled by Shanxi | Discretionary basis | 244,400 | 1.80% | 0.33% |

| Connected Distributor | Connected Client | Relationship with the Connected Distributor | Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for independent third parties | Number of Offer Shares to be allocated to the connected client | Appropriate percentage of total number of Offer Shares (assuming the Over-allotment Option is not exercised) | Approximate percentage of total issued share capital in the Company upon Listing (assuming the Over-allotment Option is not exercised) |
|-----------------------|------------------|--|---|--|--|--|
| | | Securities International Financial Holdings ("SSIFH"). | | | | |

Notes:

- (1) CSI will act as the single counterparty of a back-to-back total return swap transaction (the “**CSI Back-to-back TRS**”) to be entered into by CSI in connection with a total return swap order (the “**CSI Client TRS**”) placed and fully funded by its ultimate clients (the “**CSI Ultimate Client(s)**”), by which CSI will pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients. CSI will hold the beneficial interest of the Offer Shares on behalf of the CSI Ultimate Client on a non-discretionary basis. The CSI Ultimate Client may exercise an early termination right to early terminate the CSI Client TRS at any time from the trade date of the CSI Client TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange. Upon the final maturity or termination of the CSI Client TRS by the CSI Ultimate Client, CSI will dispose of the Offer Shares on the secondary market and the CSI Ultimate Client will receive a final termination amount of the CSI Back-to-back TRS which should have taken into account all the economic returns or economic loss in relation to the Offer Shares and the fixed amount of transaction fees of the CSI Back-to-back TRS and the CSI Client TRS. CSI will not exercise the voting right of the Offer Shares during the terms of the CSI Back-to-back TRS. CSI is not a collective investment scheme which is not authorized by the SFC, or is expected to hold the Offer Shares on behalf of such scheme.

The details of the CSI Ultimate Clients are as follows:

| Name of CSI Ultimate Client | Limited Partner/ Shareholding holding 30% or more in the CSI Ultimate Clients | Fund Manager/ General Partner | Ultimate beneficial owners of Fund Manager / General Partner |
|--|---|--|--|
| Liangpai Exclusive Fund No. 43 Private Securities Investment Fund (量派專享四十三號私募證券投資基金) | Sun Lin (孫林) | Shanghai QuantPi Investment Limited (上海量派投資管理有限公司) | Sun Lin (孫林) and Yu Hang (余航) |
| Canaan China Flagship Fund | Liang Hao | N/A | N/A |
| Hover4pi Fund I OFC | N/A | Hover4pi Capital | He Hui |

| Name of CSI Ultimate Client | Limited Partner/ Shareholding holding 30% or more in the CSI Ultimate Clients | Fund Manager/ General Partner | Ultimate beneficial owners of Fund Manager / General Partner |
|--|---|--|--|
| | | Management | |
| Tongyi Taoli No. 1 Private Securities Investment Fund (通怡桃李1號私募證券投資基金) | Wang Jing (王靜) | Shanghai Tongyi Investment Management Co., Ltd. (上海通怡投資管理有限公司) | Chu Yibo (儲貽波) |
| Tongyi Taoli No. 10 Private Securities Investment Fund (通怡桃李10號私募證券投資基金) | N/A | Shanghai Tongyi Investment Management Co., Ltd. (上海通怡投資管理有限公司) | Chu Yibo (儲貽波) |
| Heyi Xuehu No. 1 Private Securities Investment Fund (合易雪湖1號私募證券投資基金) | N/A | Beijing Heyi Yingtong Asset Management Co., Ltd (北京合易盈通資產管理有限公司) | Liu Zhe (劉喆) and Liu Yang (劉洋) |
| Evolution Darwin Shangshan No. 3 Private Securities Investment Fund (進化論達爾文上善三號私募證券投資基金) | N/A | Hainan Evolution Asset Management Co., LTD (海南進化論私募基金管理有限公司) | Wang Yiping (王一平) |
| Heijing Capital Management Co., Ltd. (黑晶資本管理有限公司) | Li Chuxin (李出新) and Shao Yukai (邵宇開) | N/A | N/A |

To the best knowledge of CSI and after making all reasonable enquiries, each of the CSI Ultimate Clients is an independent third party of the Company, its subsidiaries and substantial shareholders, CSI, CLSA and the companies which are members of the same group of CLSA.

- (2) *SSI is a non-syndicate distributor in relation to the Global Offering. In relation to the subscription, SSIAM shall hold the Offer Shares in its capacity as the discretionary fund manager on behalf of its investor holding over 30% interest (the "**SSIAM Ultimate Client**"). SSIAM is not a collective investment scheme which is not authorised by the SFC or is expected to hold the Offer Shares on behalf of such scheme. The SSIAM Ultimate Client is Zeng Jinjing (曾金晶). To the best knowledge of SSIAM, the SSIAM Ultimate Client is an independent third party of the Company, its subsidiaries, its substantial shareholders, SSIFH and the companies which are members of the same group of companies as SSIFH.*

Placing to a close associate of existing Shareholders as placee with a prior consent under paragraph 1C(2) of the Placing Guidelines

The Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to Wealth Shine, a close associate of Ruiji Phase III and Ruiji Phase X (the "**Existing Shareholders**"), each an existing Shareholder, on the following grounds which are consistent with the conditions as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide

for New Listing Applicant:

- (1) the Company will comply with the public float requirement under Rule 19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the Listing Rules;
- (2) no preference in allocation has been, nor will be, given to Wealth Shine as a placee by virtue of being a close associate of the Existing Shareholders in any allocation in the placing tranche of the Global Offering;
- (3) each of the Company, the Sole Sponsor and the Sole Overall Coordinator has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide; and
- (4) the relevant information in respect of the allocation to Wealth Shine as a placee has been disclosed in this allotment results announcement.

Such allocation of Offer Shares is in compliance with all the conditions under the consent granted by the Stock Exchange.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 12, 2026 issued by HJ Science Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

**Potential investors of the Offer Shares should note that the Sole Sponsor and the Sole Overall Coordinator (acting in such capacity and as the Underwriter and the Capital Market Intermediary) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on June 23, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately after the completion of the Global Offering (before any exercise of the Over-allotment Option), an aggregate of 39,106,162 H Shares, representing 53.13% of the total issued Shares upon the Listing which is higher than the prescribed percentage of H Shares required to be held in public hands of 25% under Rule 19A.13A(1) of the Listing Rules, will be counted towards the public float. Hence, the Company will be able to comply with Rule 19A.13A(1) of the Listing Rules.

Pursuant to the applicable PRC law, within the 12 months following the Listing Date, all existing Shareholders (including the Pre-IPO Investors) cannot dispose of any of the Shares held by them. Pursuant to the relevant cornerstone investment agreements, each Cornerstone Investor has agreed to a lock-up period of six months following the Listing Date. As such, the H Shares held by the existing Shareholders and the Cornerstone Investors upon the Listing shall not be counted towards the free float of the H Shares of the Company at the time of Listing. Based on the Offer Price of HK\$81.80 per Offer Share, the expected market value of the H Shares held by the public and not subject to disposal restrictions exceeds HK\$600,000,000. Therefore, the Company will comply with the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering (assuming the Over-allotment Option is not exercised): (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder under the Listing Rules immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, June 23, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, June 23, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, June 23, 2026 (Hong Kong time). The H Shares will be traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 6132.

By order of the Board

HJ Science Co., Ltd.

Dr. Ji Jianxin

*Executive Director, chairman of the Board,
chief executive officer and general manager*

Hong Kong, June 22, 2026

As at the date of this announcement, the executive Directors are Dr. Ji Jianxin, Mr. Yang Xiangyu, Mr. Wu Zhen and Ms. Zhang Yao; the non-executive Directors are Ms. Geng Xueli, Mr. Du Jiangbo, Mr. Wang Junfeng and Mr. Zhang Zhiyong; and the independent non-executive Directors are Mr. Wong Jovi Chi Wing, Mr. Jiang He, Ms. Lin Fangzhu and Mr. Liu Zhe.